177 related articles for article (PubMed ID: 34003067)
1. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
2. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
[TBL] [Abstract][Full Text] [Related]
3. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Rugo HS; Pennella EJ; Gopalakrishnan U; Hernandez-Bronchud M; Herson J; Koch HF; Loganathan S; Deodhar S; Marwah A; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng MLT; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Roy S; Yanez Ruiz EP; Barve A; Fuentes-Alburo A; Waller CF
Breast Cancer Res Treat; 2021 Jul; 188(2):369-377. PubMed ID: 34125340
[TBL] [Abstract][Full Text] [Related]
4. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
McBride A; Alrawashdh N; MacDonald K; Abraham I
Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
[TBL] [Abstract][Full Text] [Related]
5. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Rugo HS; Pennella EJ; Gopalakrishnan U; Hernandez-Bronchud M; Herson J; Koch HF; Loganathan S; Deodhar S; Marwah A; Manikhas A; Bondarenko I; Parra JD; Abesamis-Tiambeng MLT; Akewanlop C; Vynnychenko I; Sriuranpong V; Roy S; Yanez Ruiz EP; Barve A; Waller CF
Breast; 2021 Aug; 58():18-26. PubMed ID: 33892316
[TBL] [Abstract][Full Text] [Related]
6. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
MacDonald K; Alrawashdh N; McBride A; Abraham I
Future Oncol; 2021 Nov; 17(33):4561-4570. PubMed ID: 34382416
[TBL] [Abstract][Full Text] [Related]
7. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
[TBL] [Abstract][Full Text] [Related]
8. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
MacDonald K; Pondel M; Abraham I
J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
[TBL] [Abstract][Full Text] [Related]
9. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
10. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
DuMond B; Patel V; Gross A; Fung A; Weber S
J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.
Bernat-Peguera A; Trigueros M; Ferrando-Díez A; Ibáñez C; Bystrup S; Martínez-Cardús A; Margelí M; Martínez-Balibrea E
Breast; 2022 Apr; 62():1-9. PubMed ID: 35078146
[TBL] [Abstract][Full Text] [Related]
15. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
18. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
19. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
20. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
